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Summary Epidermal growth factor receptors were measured using a radioligand binding assay in membrane
preparations from 67 cancer and 25 non-malignant tissues.
The binding characteristics of EGFr were similar in tumour and normal breast membranes. The concentra-
tions were significantly higher in non-malignant tissue than in cancer. EGFr concentrations were directly
correlated with steroid receptors in non-malignant tissue, whereas in cancer an inverse correlation between
EGFr and steroid receptors was found.
Epidermal Growth Factor (EGF) is an important growth
regulatory factor, that acts through a specific membrane
receptor (EGFr).
EGFr was extensively studied in breast cancer where it was
expressed from 22% to 67% of cases (Koenders et al., 1991)
and showed an inverse correlation with the estrogen recep-
tors (ER) and the progesterone receptors (PR) in almost all
the studies published to date. The clinical usefulness of EGFr
is still under debate and its role in breast cancer has not yet
been definitively established. EGFr mRNA and protein were
also identified in non-malignant breast tissues. To date, few
studies have investigated the distribution of EGFr in human
non-malignant breast tissue. Using immunohistochemical
methods, EGFr was found in normal epithelium and ducts
(Damjanov et al., 1986), and its expression was shown more
frequently in non neoplastic than in cancer tissue (Moller et
al., 1989; Tauchi et al., 1989; Tsutsumi et al., 1990). The
results obtained by ligand binding assay (LBA) methods are
still conflicting (Barker et al., 1989; Ozawa et al., 1988;
Pekonen et al., 1988).
To evaluate the distribution of EGFr in breast tissue, this
protein has been quantitatively determined both in cancer
and in non-malignant tissues, and its concentration has been
compared with steroid receptors.
Processing ofbreast tissue
Tissue preparation was performed as previously described
(Dittadi et al., 1990). Briefly, tissue samples were pulverised
and homogenised in phosphate buffer. The homogenate was
centrifuged at 800 g for 10 min at 4°C. The pellet was washed
twice and the supernatants pooled and centrifuged at
100,000 g for 1 h at 4°C. The supernatant fraction was used
for ER and PR determination. The membrane pellet was
homogenised and collected for EGFr determination.
Receptor assay
ER and PR determination was performed as recommended
by the EORTC (EORTC, 1980), using a single point assay
with 4 nM concentration of tritium-labelled steroid hormone.
EGFr determination was performed by Scatchard analysis
(eight points with final concentration from 1.5 to 0.1 nM of
'25I-EGF) according to EORTC Receptor Study Group (Ben-
raad & Foekens, 1990).
Steroid and EGF receptor results were expressed as fmoles
per mg of protein. EGFr assay was performed only in speci-
mens containing more than 0.3 mg of proteinml'.
Statistical analysis was performed using Spearman rank
correlation, Wilcoxon rank sum, Kruskall-Wallis and Chi-
square tests.
Material and methods
Patients
Sixty-seven patients with primary breast carcinoma have been
evaluated (median age: 60 years, range 46-78).
In addition, 25 samples of non-malignant breast tissue
were collected from six premenopausal and 19 post-
menopausal women who underwent surgery for mammoplas-
tic or benign breast disease.
Samples of both tumour tissue and non-malignant tissue
were collected freshly at the time of operation from each
patient and stored in liquid nitrogen.
Representative pieces of both cancer and non car-
cinomatous specimens were collected before the tissue
homogenisation and histologically verified. We considered as
normal the breast tissue samples in which normal glandular
component was represented. Among the benign breast
disease samples, ten were fibroadenomas and three were
fibrocystic disease.
Results
Table I shows the concentrations of ER, PR and EGFr in
non-malignant and cancer samples. No differences in ER, PR
and EGFr concentratioons were found between normal
breast and benign disease samples (data not shown). The two
types of samples were therefore considered as one group and
identified as non-malignant samples.
TableI Estrogen, progesteroneandepidermal growth factorreceptors
in breast tissue (fmol mg ' prot.)
Cancer Non-malignant
ER
median 69.8 4.8
min-max 0-1318 0-29.1
P (Mann-Whitney) <0.001
PR
median 79.7 17.0
min-max 0-1883 0-74.4
P (Mann-Whitney) 0.01
EGFR
median 4.2 49.3
min-max 0-1194 2.7-213
P (Mann-Whitney) <0.001
n 67 25
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ER and PR showed lower concentrations in non-malignant
tissue than in cancer. High affinity EGFr (median Kd:
0.24 nM, range: 0.03-0.69) was present in all non-malignant
tissue samples evaluated.
EGFr were present in 58.2% of cancer samples, the con-
centration being significantly lower than in non-malignant
tissue (Figure 1). The affinity constant of EGFr ranged
between 0.03 and 0.9 nM (median 0.33 nM), without
differences with respect to non-malignant tissue. Due to the
lack of an established + / - cut-off value, we classified as
EGFr positive the samples in which EGFr was detectable
and as EGFr negative the samples without receptors.
We have correlated (Spearman rank correlation) EGFr
with SR in the specimens evaluated. In non-malignant tissue
a significant direct correlation between EGFr and both ER
and PR was found (Figure 2). Conversely, in cancer tissue a
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Figure 1 EGFr distribution in different breast tissues. Solid
horizontal lines indicate the median of concentrations. In non-
malignant tissue, circles indicate benign disease specimens and
asterisks indicate normal specimens.
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Figure 2 Correlation between EGFr and steroid receptors (SR)
in non-malignant tissue.
EGFr vs ER (*): r = 0.470, P<0.05.
EGFr vs PR (0): r = 0.424, P<0.05.
negative correlation was found between EGFr and both ER
and PR (Figure 3). A X2 analysis confirmed the inverse
relationships between EGFr expression and both ER and PR
in breast cancer (Table II). EGFr was present in 92% of SR
negative and in 48% of SR positive specimens (Figure 4).
Discussion
The presence of EGFr was demonstrated by immuno-
histochemical methods in non-malignant breast tissue. Dam-
janov et al. (1986) show strong positive staining for EGFr in
normal ductal and myoepithelial cells. Breast cancer cells
showed lower expression than in normal gland (M6ller et al.,
1989; Tsutsumi et al., 1990) and in fibroadenomas (Tauchi et
al., 1989).
Using a ligand binding method Ozawa et al. (1988) found
higher EGFr concentrations in a small series of breast cancer
tissues in comparison to non-malignant tissue, while Pekonen
et al. (1988) did not find differences between EGFr binding in
cancer and in corresponding normal tissues. Barker et al.
(1989) showed similar concentrations but more frequent exp-
ression in non-malignant tissue than in cancer.
These conflicting results may be due, not only to the small
number of studies, but also to the differences and lack of
standardisation between the binding assays used.
Using a standardised method according to the EORTC
Receptor Study Group we found detectable high affinity
EGFr in all non-malignant samples evaluated.
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Figure 3 Correlation between EGFr and steroid receptor (SR) in
cancer tissue.
EGFr vs ER (*): r -0.350, P<0.01.
EGFr vs PR (0): r -0.271, P<0.05.
The two samples with estrogen and progesterone receptors above
1200 fmol mg-' prot. are not represented.
Table II EGFr positivity rates. Relationships with steroid receptors
ER PR
+ - +_
+ 27/67 12/67 25/67 14/67
(%) 40.3 17.9 37.3 20.9
EGFr
- 27/67 1/67 26/67 2/67
(%) 40.3 1.5 38.8 3.0
P 0.014 0.015
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Figure 4 EGFr positive ( ~ and negative ( I ) cases in
different steroid receptors (SR) phenotypes. Bars represent per-
centage of total samples.
In breast cancer specimens we found high affinity EGFr in
less than 60% of cases. Moreover, in non-malignant speci-
mens EGFr was directly correlated to both ER and PR,
whereas in cancer tissue it showed an inverse relationship
with steroid receptor, in agreement with the majority of
published studies.
The finding of an opposite relationship between EGFr and
steroid receptor in cancer with respect to non-malignant
tissue confirm a trend previously indicated (Barker et al.,
1989). In particular, while almost all SR negative samples
show detectable EGFr, 52% of SR + samples were EGFr
negative.
We describe here, to our knowledge, for the first time, not
only a more frequent but an unequivocally higher expression
of EGFr in non-malignant samples than in cancer tissue.
This finding emphasises the importance of sampling repre-
sentative breast cancer tissue for EGFr assay since small
quantities of non-malignant tissues may cause a severe
overestimate of the EGFr level. The results suggest also that
the possibility of a different role of EGF/EGFr loop should
be investigated in SR + and SR - breast tumours.
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